Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 16.5 0.00% 0.00
ACOR closed unchanged on Wednesday, April 26, 2017, on 82 percent of normal volume.

Earnings due: Apr 27

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ACOR trend table...

Date Alert Name Type % Chg
Apr 26 Doji - Bearish? Reversal 0.00%
Apr 26 1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Apr 26 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Apr 24 NR7 Range Contraction 3.13%
Apr 24 Narrow Range Bar Range Contraction 3.13%
Apr 24 Slingshot Bearish Bearish Swing Setup 3.13%
Apr 21 New 52 Week Low Bearish 4.10%
Apr 21 Narrow Range Bar Range Contraction 4.10%
Apr 20 Narrow Range Bar Range Contraction 3.45%
Apr 20 Doji - Bullish? Reversal 3.45%

Older signals for ACOR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 15.6
Average Volume 1,220,394
200-Day Moving Average 22.2822
50-Day Moving Average 23.1176
20-Day Moving Average 17.9575
10-Day Moving Average 16.33
Average True Range 1.0702
ADX 32.9
+DI 17.18
-DI: 31.08
Chandelier Exit (Long, 3 ATRs) 26.5394
Chandelier Exit (Short, 3 ATRs) 18.8106
Upper Bollinger Band 24.2944
Lower Bollinger Band 11.6206
Percent B (%b) 0.38
Bandwidth 0.705766